Study details
Enrolling now
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
Novartis Pharmaceuticals
NCT IDNCT07217067ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
165
Study length
about 1.9 years
Ages
18+
Locations
5 sites in MS, NC, NY +2
What this study is about
Researchers are testing a treatment called PKN605 for people with atrial fibrillation. The trial will last 681 days and involve approximately 165 participants who are randomly assigned to receive either PKN605 or a placebo.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take PKN605
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Pharmacokinetic Parameter: concentration
Body systems
Cardiology / Heart